Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Mol Cancer Ther. 2008 Jul;7(7):1900–1908. doi: 10.1158/1535-7163.MCT-08-0012

(A) SK-parental and SK-HRp2, (B) BT-parental and BT-HRp3 cells were treated with NDGA (40 μM), trastuzumab (20 μg/mL), or a combination of both drugs for 72 h, at which point drug-containing media was removed and cells were maintained in drug-free media for an additional week. Colonies were then stained with methylene blue. Experiments were repeated at least twice, in duplicate each time. Representative colony assays are shown. The combination of NDGA plus trastuzumab inhibited cell survival to a greater degree than either agent alone, suggesting that NDGA partially restores trastuzumab efficacy to trastuzumab-refractory breast cancer cells.

(A) SK-parental and SK-HRp2, (B) BT-parental and BT-HRp3 cells were treated with NDGA (40 μM), trastuzumab (20 μg/mL), or a combination of both drugs for 72 h, at which point drug-containing media was removed and cells were maintained in drug-free media for an additional week. Colonies were then stained with methylene blue. Experiments were repeated at least twice, in duplicate each time. Representative colony assays are shown. The combination of NDGA plus trastuzumab inhibited cell survival to a greater degree than either agent alone, suggesting that NDGA partially restores trastuzumab efficacy to trastuzumab-refractory breast cancer cells.